The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).
 
Debashish Tripathy
Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; Gilead Sciences; GlaxoSmithKline; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Kashif Ali
No Relationships to Disclose
 
Laila Agrawal
Honoraria - AstraZeneca; AstraZeneca; Breast Cancer Index; Gilead Sciences; Hologic; immunomedics; Pfizer; Puma Biotechnology
Speakers' Bureau - Lilly
Travel, Accommodations, Expenses - Lilly
(OPTIONAL) Uncompensated Relationships - After Cancer
 
Sami M. Ali
Employment - The Oncology Institute of Hope and Innovation
Stock and Other Ownership Interests - The Oncology Institute of Hope and Innovation
 
Sibel Blau
Employment - Northwest Medical Specialties
Leadership - Northwest Medical Specialties; Quality Cancer Care Alliance
Stock and Other Ownership Interests - All4cure (I); Northwest Medical Specialties
Honoraria - American Journal of Managed Care; Cardinal Health; Novartis; Puma Biotechnology
Consulting or Advisory Role - Billion to One; IntegraConnect
Research Funding - Northwest Medical Specialties
Expert Testimony - Northwest Medical Specialties
Travel, Accommodations, Expenses - Northwest Medical Specialties; Quality Cancer Care Alliance
Other Relationship - All4Cure (I); Exigent Research; Northwest Medical Specialties; Quality Cancer Care Alliance
 
Margaret Block
Consulting or Advisory Role - Theranostics Health
 
Michael A. Danso
Honoraria - Amgen
Consulting or Advisory Role - Immunomedics; Novartis; Pfizer; Seagen
 
Denise Yardley
Consulting or Advisory Role - Athenex; Biotheranostics; Bristol-Myers Squibb; G1 Therapeutics; Immunomedics; Lilly; Novartis; Sanofi/Aventis
Speakers' Bureau - Genentech/Roche; Novartis
Research Funding - Abbvie; Amgen; Biomarin; Biothera; Clovis Oncology; Genentech/Roche; Incyte; Lilly; MacroGenics; MedImmune; Medivation; Merck; Nektar; Novartis; Odonate Therapeutics; Pfizer; Polyphor; Tesaro
Travel, Accommodations, Expenses - Genentech/Roche; Novartis
 
Jay Andersen
Consulting or Advisory Role - AstraZeneca; Athenex; Biotheranostics; Genentech; Genomic Health; Gilead Sciences; Merck; Myriad Genetic Laboratories; Novartis; Puma Biotechnology; Seagen
Research Funding - Ambrx (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst)
 
Adrienne Gropper Waks
Consulting or Advisory Role - AstraZeneca
Research Funding - Genentech (Inst); Gilead Sciences (Inst); MacroGenics (Inst); Merck (Inst)
 
Priya Jayachandran
Research Funding - Ambrx (Inst)
 
Igor Makhlin
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer Health; Gilead Sciences
 
Petros Nikolinakos
Research Funding - Ambrx (Inst)
 
Richard Zuniga
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Mirat Therapeutics
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Agendia; Aptitude Health; AstraZeneca; Daiichi Sankyo; DAVA Oncology; Eisai; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Roche; Seagen
 
Sandra Aung
Employment - Ambrx
Leadership - Ambrx
Stock and Other Ownership Interests - Ambrx
 
Janice M. Lu
Employment - Ambrx
Leadership - Ambrx
Stock and Other Ownership Interests - Ambrx
Honoraria - Daiichi Sankyo; Lilly; Sanofi/Aventis
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Sanofi/Aventis
Research Funding - Genentech (Inst); Lilly (Inst); Novartis (Inst); Radius Health (Inst)
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
William John Gradishar
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Gilead Sciences; merck; Novartis; Pfizer
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)